Zanubrutinib
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Zanubrutinib: From Mantle Cell Lymphoma to Myeloid Leukemia
One-Sentence Summary
Zanubrutinib is an oral BTK inhibitor, originally used for B-cell cancers such as mantle cell lymphoma. The TxGNN model predicts it may be effective for myeloid leukemia, but only 1 clinical trial (a Phase 1 study in which zanubrutinib is only a possible combination partner) and no directly relevant publications support this direction. The high model score is therefore not yet backed by clinical data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mantle cell lymphoma, B-cell neoplasm, lymphosarcoma (the Singapore licence record has no indication text) |
| Predicted New Indication | Myeloid leukemia |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor. Its efficacy in B-cell malignancies is well documented, and mechanistically it may be applicable to myeloid leukemia.
BTK is a key mediator of B-cell receptor signaling in B-cell cancers. It is also expressed in myeloid-lineage cells and has been implicated in signaling in acute and chronic myeloid leukemia. This is the main biological basis for the prediction.
However, the publications compiled for this report are almost entirely about B-cell malignancies (CLL/SLL, mantle cell lymphoma, Waldenström's macroglobulinemia), not myeloid leukemia. The only trial retrieved tests a different drug (PRT2527, a CDK9 inhibitor), and zanubrutinib appears there only as a possible combination partner in B-cell cohorts. The high TxGNN score is not backed by direct clinical data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05665530 | Phase 1 | Completed | 86 | Dose-escalation study of PRT2527 (a CDK9 inhibitor) alone or combined with zanubrutinib or venetoclax in relapsed/refractory blood cancers. It evaluates safety, tolerability and preliminary efficacy. Zanubrutinib is only a combination partner, with no myeloid leukemia efficacy data for it. |
Literature Evidence
None of the publications below directly studies zanubrutinib in myeloid leukemia. They show zanubrutinib's profile in related blood cancers.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39647999 | 2025 | RCT (Phase 3) | J Clin Oncol | SEQUOIA: 5-year follow-up of zanubrutinib vs bendamustine + rituximab in untreated CLL/SLL |
| 36400069 | 2023 | Cohort (Phase 2) | Lancet Haematol | Zanubrutinib in B-cell malignancies in patients intolerant of earlier BTK inhibitors |
| 40334067 | 2025 | Cohort | Blood Adv | Updated results: zanubrutinib is well tolerated and effective in CLL/SLL after intolerance to ibrutinib/acalabrutinib |
| 40829104 | 2026 | Cohort | Blood Adv | Pooled analysis of zanubrutinib in high-risk CLL/SLL with del(17p) and/or TP53 mutation (N = 301) |
| 34959482 | 2021 | Review | Pharmaceutics | Tyrosine kinase inhibitors in chronic leukemias, covering CML (BCR-ABL1) and CLL (B-cell receptor signaling) |
| 36402930 | 2023 | Review | Leukemia | BTK inhibitors in Waldenström's macroglobulinemia |
| 37150651 | 2023 | Review | Clin Lymphoma Myeloma Leuk | Hepatitis B virus reactivation in patients receiving BTK inhibitors |
| 42192981 | 2026 | Review | Cancers | BTK inhibitors in CLL: selectivity, hypogammaglobulinemia and infection risk |
| 38288815 | 2024 | Review | Anticancer Agents Med Chem | Synthetic methods of FDA-approved anticancer drugs (2018-2021); no clinical efficacy data |
| 36325357 | 2022 | Case report | Front Immunol | Rare coexistence of Waldenström macroglobulinemia and B-cell acute lymphoblastic leukemia |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16341P | BRUKINSA™ CAPSULE 80MG | Capsule (oral) | Not stated in the licence record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BTK inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count with differential, plus liver and renal function, as general monitoring for anticancer therapy; specific schedules should follow the package insert |
| Handling Protection | Please refer to the package insert and local institutional policy for antineoplastic drug handling |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interacting drugs. Major-level interactions include:
- Aprepitant
- Acetylsalicylic acid (aspirin)
- Dexamethasone
- Clarithromycin
- Cobicistat
- Deferasirox
- Deferiprone
- Samarium (153Sm) lexidronam
- Ibritumomab tiuxetan
- Tositumomab (I-131)
Moderate-level interactions include cimetidine, miconazole and clotrimazole.
- Class-related risks reported in the literature: Hepatitis B virus reactivation has been described with BTK inhibitors. Reviews also describe hypogammaglobulinemia and increased infection risk.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but no clinical study has tested zanubrutinib in myeloid leukemia. The only trial retrieved is a Phase 1 study of a different drug, and the supporting literature concerns B-cell malignancies. Zanubrutinib is already marketed in Singapore, but the evidence for this new indication is limited to a mechanistic hypothesis.
To proceed, the following is needed:
- Preclinical or early clinical data on zanubrutinib in myeloid leukemia (AML or CML)
- Detailed mechanism of action data (MOA)
- Package insert warnings and contraindications from the Singapore HSA
- A review of the major drug interactions (CYP3A-related agents, antiplatelet drugs) for the target patient population
- Confirmation of whether the NCT05665530 cohorts include any myeloid leukemia patients
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.